FindTrial
Sign In

Safety and Efficacy of Polyene Phosphatidylcholine Capsules Against Anti-Tuberculosis Drugs Induced Liver Toxicity

Safety and Efficacy of Polyene Phosphatidylcholine Capsules Against Anti-Tuberculosis Drugs Induced

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004882
Enrollment
Unknown
Registered
2014-05-26
Start date
2014-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Tuberculosis

Interventions

Group I:treated with isoniazid, rifampicin, ethambutol and
Group II:treated with isoniazid, rifampicin, ethambutol, py

Sponsors

Meizhou People's Hospital, Gaungdong Province
Lead Sponsor

Eligibility

Age
14 Years to No maximum

Inclusion criteria

Inclusion criteria: Tuberculosis cases (including pulmonary tuberculosis, tuberculous pleurisy, etc.;14 years and older. normal serum alanine transaminase enzyme level and normal serum bilirubin level; No hepatocirrhosis history.

Exclusion criteria

Exclusion criteria: Previous anti-TB chemotherapy; Be allergic to experiment drugs; Refuse to participate.

Design outcomes

Primary

MeasureTime frame
alanine aminotransferase;aspartate aminotransferase;bilirubin;—

Countries

China

Contacts

Public ContactYan-jia Du
695724176@qq.com+86 13411268557

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026